These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 32841416

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines.
    McLemore LE, Albarracin CT, Gruschkus SK, Bassett RL, Wu Y, Dhamne S, Yim I, Lin K, Bedrosian I, Sneige N, Chen H.
    Breast Cancer Res Treat; 2021 May; 187(1):95-104. PubMed ID: 33813685
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Reappraisal of HER2 Amplification in High-Grade Urothelial Carcinoma Based on 2018 ASCO/CAP Clinical Practice Guidelines.
    Mohanty SK, Mishra SK, Tiwari A, Sharma S, Bhardwaj M, Pattnaik N, Jaiswal S, Baisakh MR, Das S, Pradhan MR, Swain TR, Satpathy K, Williamson SR, Parwani AV.
    Am J Clin Pathol; 2021 Nov 08; 156(6):1130-1141. PubMed ID: 34124742
    [Abstract] [Full Text] [Related]

  • 46. Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
    Middleton LP, Price KM, Puig P, Heydon LJ, Tarco E, Sneige N, Barr K, Deavers MT.
    Arch Pathol Lab Med; 2009 May 08; 133(5):775-80. PubMed ID: 19415952
    [Abstract] [Full Text] [Related]

  • 47. The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines.
    Long TH, Lawce H, Durum C, Moore SR, Olson SB, Gatter K, Troxell ML.
    Am J Clin Pathol; 2015 Aug 08; 144(2):253-62. PubMed ID: 26185310
    [Abstract] [Full Text] [Related]

  • 48. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC, Pettit AS, Veldhuijzen van Zanten D, Barnes PJ.
    Histopathology; 2017 May 08; 70(6):966-974. PubMed ID: 28032917
    [Abstract] [Full Text] [Related]

  • 49. Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.
    Pu X, Shi J, Li Z, Feng A, Ye Q.
    Pathol Res Pract; 2015 Jun 08; 211(6):421-5. PubMed ID: 25818873
    [Abstract] [Full Text] [Related]

  • 50. Integrated genomic characterization of ERBB2/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups.
    Yang SR, Bouhlal Y, De La Vega FM, Ballard M, Kuo CJ, Vilborg A, Jensen G, Allison K.
    Mod Pathol; 2020 Aug 08; 33(8):1546-1556. PubMed ID: 32161378
    [Abstract] [Full Text] [Related]

  • 51. Assessment of HER2 status in invasive breast cancers with increased centromere 17 copy number.
    Jang MH, Kim EJ, Kim HJ, Chung YR, Park SY.
    Breast Cancer Res Treat; 2015 Aug 08; 153(1):67-77. PubMed ID: 26223814
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y, Yang W, Yang F, Lu Y, Cai X, Zhou X.
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr 08; 43(4):226-30. PubMed ID: 24915811
    [Abstract] [Full Text] [Related]

  • 55. [Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1 780 cases of invasive breast cancers].
    Xu Y, Bai QM, Yang F, Zhu XL, Lu YM, Zhang J, Yang WT, Zhou XY.
    Zhonghua Bing Li Xue Za Zhi; 2016 Aug 08; 45(8):545-9. PubMed ID: 27510780
    [Abstract] [Full Text] [Related]

  • 56. Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results.
    Geiersbach KB, Sill DR, Del Rosario KM, Meyer RG, Spears GM, Yuhas JA, Sukov WR, Jenkins RB, Ocal IT, Mounajjed T, Chen B.
    Am J Clin Pathol; 2021 Oct 13; 156(5):886-894. PubMed ID: 33942843
    [Abstract] [Full Text] [Related]

  • 57. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
    Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P.
    Arch Pathol Lab Med; 2014 Feb 13; 138(2):213-9. PubMed ID: 24164555
    [Abstract] [Full Text] [Related]

  • 58. UK recommendations for HER2 assessment in breast cancer: an update.
    Rakha EA, Tan PH, Quinn C, Provenzano E, Shaaban AM, Deb R, Callagy G, Starczynski J, Lee AHS, Ellis IO, Pinder SE.
    J Clin Pathol; 2023 Apr 13; 76(4):217-227. PubMed ID: 36564170
    [Abstract] [Full Text] [Related]

  • 59. An Evaluation of Clinicopathological Correlation and Outcome of Human Epidermal Growth Factor Receptor 2 Subgroups Reclassified According to the Latest ASCO/CAP Guideline.
    Wang C, Tsang JY, Poon IK, Shao Y, Li JJ, Shea KH, Hlaing T, Wong SI, Tse GM.
    Clin Breast Cancer; 2022 Jan 13; 22(1):e114-e122. PubMed ID: 34119429
    [Abstract] [Full Text] [Related]

  • 60. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
    Solomon JP, Dell'Aquila M, Fadare O, Hasteh F.
    Am J Clin Pathol; 2017 Apr 01; 147(4):432-437. PubMed ID: 28340220
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.